Global Non-Invasive Cancer Diagnosis Market Hits $38.6 billion in 2025 with 12.2% CAGR

Global non-invasive cancer diagnosis market was valued at $38.6 billion in 2025 and is growing at a CAGR of 12.2% during the forecast period (2026-2035). Molecular diagnostics play a critical role in the global non-invasive cancer diagnosis market by enabling highly sensitive detection of circulating tumor DNA (ctDNA) and other biomarkers in blood. These tests support early identification of cancer recurrence and residual disease, often months before conventional imaging methods can detect abnormalities. By providing precise, real-time insights, molecular diagnostics allow clinicians to personalize monitoring strategies, optimize treatment decisions, and improve patient outcomes. The minimally invasive nature of these tests enhances patient compliance and reduces reliance on traditional biopsies, driving adoption across healthcare systems and contributing significantly to the growth and innovation of the non-invasive cancer diagnosis market.

Browse the full report description of “Non-Invasive Cancer Diagnosis Market Size, Share & Trends Analysis by Type (Blood Cancer, Solid Tumors, Breast Cancer, Lung Cancer, and Others), By Techniques (Clinical Chemistry, Immunochemistry/Immunoassay, Molecular Diagnostics, and Other Clinical Instruments), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/non-invasive-cancer-diagnostics-market

Moreover, non-invasive tests detecting circulating tumor DNA (ctDNA) in blood are increasingly enabling earlier identification of cancer recurrence compared with traditional imaging, supporting more timely interventions and personalized patient care. This growing capability is driving demand for precise monitoring solutions and expanding the global non-invasive cancer diagnosis market. For instance, in January 2026, Labcorp expanded its molecular residual disease (MRD) testing to monitor recurrence risks for breast, lung, and colon cancer. The tests, which can detect cancer recurrence earlier than traditional imaging, include the Labcorp Plasma Detect ID for stage I–III breast cancer and stage I–IIIA lung cancer, as well as the Labcorp Plasma Detect Genome for stage III colon cancer. Currently, cancer recurrence remains a concern, with rates reaching 35% for stage III colon cancer, 10-40% for stage I-III breast cancer, and 10-55% for non-small cell lung cancer. MRD testing detects circulating tumor DNA (ctDNA) in the bloodstream, indicating recurrence months in advance. Both tests can detect ctDNA levels as low as 0.005%, enabling oncologists to refine monitoring strategies and provide clarity to patients during uncertain times.

Key Innovators Driving Non-Invasive Cancer Diagnosis Transformation

The key players in the non-invasive cancer diagnosis market include Illumina, Inc., Johnson & Johnson, Roche Diagnosis, Siemens Healthineers, Thermo Fisher Scientific, among others. These companies are driving innovation in digital health solutions, including telemedicine, electronic health records, remote patient monitoring, and AI-powered clinical tools, thereby shaping the future of healthcare delivery globally.

• In October 2024, developed a new non-invasive optical diagnostic method for early cancer detection, published in Biosensors & Bioelectronics. This approach utilizes a specialized sensor material to amplify optical signals from cancer metabolites in biofluids like saliva, offering an alternative to traditional methods such as blood draws and biopsies. In collaboration with Chonnam National University Hospital, colorectal cancer diagnosis was demonstrated using a plasmonic needle that enhances Raman optical signals during colonoscopy. The sensor employs surface-enhanced Raman scattering (SERS) and addresses saliva’s viscosity with a hierarchical nanoarchitecture for improved analysis. For lung cancer detection, artificial intelligence is used to identify relevant biomarkers.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By Techniques
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Illumina, Inc., Johnson & Johnson, Roche Diagnosis, Siemens Healthineers, Thermo Fisher Scientific, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Non-Invasive Cancer Diagnosis Market Report Segment

By Type

• Blood Cancer
• Solid Tumors
• Breast Cancer
• Lung Cancer
• Others

By Techniques

• Clinical Chemistry
• Immunochemistry/Immunoassay
• Molecular Diagnostics
• Other Clinical Instruments

Global Non-Invasive Cancer Diagnosis Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/non-invasive-cancer-diagnostics-market